probucol has been researched along with Insulin Resistance in 4 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, we have tested whether the previously proven blood-brain barrier protective agent, probucol, can prevent blood-brain barrier breakdown and cognitive decline in a dietary-induced murine model of diabetic insulin resistance." | 3.91 | Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet. ( Al-Salami, H; Brook, E; Fimognari, N; Lam, V; Mamo, JC; Mooranian, A; Nesbit, M; Takechi, R, 2019) |
| "Probucol (PB) is an hypolipidaemic drug with potential antidiabetic effects." | 1.48 | The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. ( Al-Salami, H; Al-Sallami, H; Mamo, J; Mooranian, A; Negrulj, R; Takechi, R, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mooranian, A | 2 |
| Negrulj, R | 1 |
| Takechi, R | 2 |
| Mamo, J | 1 |
| Al-Sallami, H | 1 |
| Al-Salami, H | 2 |
| Mamo, JC | 1 |
| Lam, V | 1 |
| Brook, E | 1 |
| Fimognari, N | 1 |
| Nesbit, M | 1 |
| Yasunari, K | 1 |
| Kohno, M | 1 |
| Kano, H | 1 |
| Yokokawa, K | 1 |
| Minami, M | 1 |
| Yoshikawa, J | 1 |
| Pfuetze, KD | 1 |
| Dujovne, CA | 1 |
1 review available for probucol and Insulin Resistance
| Article | Year |
|---|---|
Probucol.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Apolipoproteins E; Arteriosclerosis; Cardiovascular | 2000 |
3 other studies available for probucol and Insulin Resistance
| Article | Year |
|---|---|
The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Blood Glucose; Capsules; Cytokines; Diet, H | 2018 |
Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Blood-Brain Barrier; Cerebral Cortex; Cognition | 2019 |
Antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose.
Topics: Animals; Antioxidants; Becaplermin; Biological Transport, Active; Cell Cycle; Cell Division; Cell Mo | 1999 |